234 related articles for article (PubMed ID: 19487912)
1. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Benjamin L; Buthion V; Iskedjian M; Farah B; Rioufol C; Vidal-Trécan G
J Med Econ; 2013; 16(1):96-107. PubMed ID: 22970840
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
Poncet B; Colin C; Bachelot T; Jaisson-Hot I; Derain L; Magaud L; Fournel-Federico C; Mousseau M; Tigaud JD; Jacquin JP; Trillet-Lenoir V
Am J Clin Oncol; 2009 Aug; 32(4):369-74. PubMed ID: 19381078
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
9. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
[TBL] [Abstract][Full Text] [Related]
10. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
15. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
16. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
17. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
18. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
Esposito A; Munzone E; Bagnardi V; Adamoli L; Sciandivasci A; Cullurà D; Goldhirsch A; Nolè F
Anticancer Drugs; 2012 Nov; 23(10):1089-98. PubMed ID: 22760210
[TBL] [Abstract][Full Text] [Related]
19. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
